Krystal Biotech Inc (KRYS) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Krystal Biotech Inc   (NASDAQ: KRYS)


Krystal Biotech Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Krystal Biotech Inc 's ROA in the third quarter of 2026?
Krystal Biotech Inc achieved a return on average assets (ROA) of 15.43 % in its third quarter of 2026, this is above KRYS's average return on assets of -4.99%.
Krystal Biotech Inc assets over the 12 months ending in its third quarter of 2026 are valued at $1,459 million

ROA fell compared to the second quarter of 2026, despite the net income growth of 15.15% from the second quarter of 2026.

However, within the Healthcare sector 61 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 279, from total ROA ranking in the second quarter of 2026 at 328.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Total Assets Change 29.6 % 33.07 % 30.76 % 10.42 % 26.29 %
Y / Y Net Income Change -20.53 % 42.87 % 56.53 % 13.02 % 192 %
Net Income (TTM) in million 225 241 225 205 199
Return On Assets (TTM) 15.43 % 17.65 % 17.66 % 17.18 % 17.13 %
KRYS's Total Ranking # 279 # 328 # 284 # 388 # 465
Total Assets (TTM) in million 1,600 1,507 1,397 1,334 1,235
Seq. Total Assets Change 6.17 % 7.88 % 4.74 % 8.03 % 9.01 %
Seq. Net Income Change 15.15 % -2.08 % 8.82 % -35.24 % 107.04 %

KRYS's 5 Years Annual ROA >> Back to KRYS Management Effectiveness >> Compare KRYS ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 13
Sector # 62
Overall # 329

Return On Assets Statistics
High Average Low
17.65 %
-4.99 %
-23.89 %
(Jun 30 2026)   (Jun 30 2023)



  News about Krystal Biotech Inc Return on Assets ROA

Jeune Aesthetics KB301 Shines in Phase 1, Promises New Standard in Anti-Aging Treatments,

Jeune Aesthetics Unveils a New Era in Anti-Aging: Phase 1 Breakthrough Results for KB301In an era where the quest for youthfulness and ageless beauty has gained unprecedented momentum, Jeune Aesthetics has unveiled positive interim results for their breakthrough anti-aging treatment, KB301. Examined in a Phase 1 clinical trial, KB301 has shown promising safety and efficacy in addressing two specific aging concerns: lateral canthal lines, commonly known as crow’s feet, and dynamic wrinkles of the décolleté. Enthralling Phase 1 FindingsConducted meticulously, the Phase 1 trial assessed the performance of KB301 in a diverse cohort, with a focus on safety and initial efficacy. The results, which Jeune Aesthetics announced with deserved enthusiasm, are not merely a stride but a leap in the realm of aesthetic medicine. Participants exhibited notably smoother lateral canthal lines and a marked reduction in dynamic wrinkles on the delicate décolleté area. These promising indicators underscore KB301 s potential to become a cornerstone in the aesthetic industry. Preparing for a Pivotal Phase 2 StudyGiven the compelling Phase 1 outcomes, Jeune Aesthetics has set their sights on an imminent Phase 2 study focusing expressly on the décolleté indication. Expected to commence next year, this phase will further elucidate KB301 s efficacy and long-term safety, potentially setting a new standard in targeted anti-aging treatments. Jeune Aesthetics strategic decision to elevate the décolleté as the pivotal focus for Phase 2 highlights the significant, unmet demand for effective treatments in this often-overlooked yet age-revealing area.



Financial Statements
Krystal Biotech Inc 's Assets $ 1,600 million KRYS's Balance sheet
Krystal Biotech Inc 's Income $ 63 million Quarterly KRYS's Income Statement
KRYS's Income by Division See KRYS's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2021		 (Dec 31 2020)
FY 2020
Y / Y Total Assets Change 21.02 % 48.57 % 47.01 % 76.91 % 49.57 %
Total Assets in million 1,462 1,208 813 553 313
Y / Y Net Income Change 129.74 % 715.58 % - - -
Net Income in million 205 89 11 -140 -32
Annual Return On Assets 14.01 % 7.38 % 1.34 % -25.31 % -10.29 %

KRYS's 5 Years Annual ROA >> Back to KRYS Management Effectiveness >> Compare KRYS ROA to its Competitors



Comment on KRYS's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 14.01 % compared to prior year, due to annual net income growth of 129.74 % to $204.83 million, while value of Krystal Biotech Inc 's overall assets grew just by 21.02 % to $1,461.86 million, compared to $1,461.86 a year before.


More Return On Assets Ratios
KRYS's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KRYS's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KRYS's Competitors
Subscribers only: Roa for Krystal Biotech Inc 's Suppliers
Subscribers only: Return On Assets for KRYS's Customers

You may also want to know
KRYS's Roi KRYS's Inventory Turnover Ratio KRYS's Growth Rates KRYS's Dividend Comparisons
KRYS's Profitability Ratios KRYS's Asset Turnover Ratio KRYS's Dividend Growth
KRYS's Roe KRYS's Valuation Ratios KRYS's Financial Strength Ratios KRYS's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector ROA
Aurinia Pharmaceuticals Inc   40.63 %
Nurix Therapeutics Inc   38.61 %
Indivior Pharmaceuticals Inc   36.35 %
Rallybio Corporation  34.55 %
Idexx Laboratories Inc  34.05 %
Zevra Therapeutics Inc   26.33 %
Caredx Inc   25.74 %
Medpace Holdings Inc   24.47 %
Acadia Pharmaceuticals Inc   21.60 %
Standard Biotools Inc   21.56 %
Eli Lilly And Company  21.24 %
Iradimed Corporation  20.89 %
Resmed Inc   18.67 %
Alector Inc   18.37 %
Corcept Therapeutics Inc  18.09 %
Chemed Corporation  17.73 %
Halozyme Therapeutics Inc   17.26 %
Pro dex Inc   16.75 %
Denali Therapeutics Inc   16.42 %
Krystal Biotech Inc   15.48 %
West Pharmaceutical Services Inc   15.47 %
Dexcom Inc   15.47 %
Intuitive Surgical Inc   14.71 %
Vertex Pharmaceuticals Inc  14.16 %
Neurocrine Biosciences Inc   13.69 %
Illumina Inc   13.43 %
Healthcare Services Group Inc   12.79 %
Kiniksa Pharmaceuticals International Plc  12.64 %
Tenet Healthcare Corp  12.39 %
Hca Healthcare Inc   11.73 %

Date modified: 2026-11-03T10:00:55+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.